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Abstract
Background: Cervical cancer is one of the most common AIDS-related malignancies in Thailand. To prevent
cervical cancer, The US Public Health Service and The Infectious Disease Society of America have recommended
that all HIV-infected women should obtain 2 Pap smears 6 months apart after the initial HIV diagnosis and, if
results of both are normal, should undergo annual cytological screening. However, there has been no evidence in
supporting whether this guideline is appropriate in all settings - especially in areas where HIV-infected women are
living in resource-constrained condition.
Methods: To determine the appropriate interval of Pap smear screenings for HIV-infected Thai women and risk
factors for subsequent abnormal cervical cytology, we assessed the prevalence, cumulative incidence and
associated factors of cervical cell abnormalities (atypical squamous cell of undetermined significance or higher
grades, ASCUS+) among this group of patients.
Results: The prevalence of ASCUS+ was 15.4% at the first visit, and the cumulative incidence of ASCUS+ gradually
increased to 37% in the first 3.5 years of follow-up appointments (first 7 times), and tended to plateau in the last
2 years. For multivariate correlation analysis, women with a CD4 count <350 cells/μL had a significant correlation
with ASCUS+ (P = 0.043). There were no associations of subsequent ASCUS+ with age, pregnancy, contraceptive
method, highly active anti-retroviral treatment, assumed duration of infection, or the CD4 count nadir level.
Conclusion: There are high prevalence and cumulative incidence of ASCUS+ in HIV-infected Thai women. With a
high lost-to-follow-up rate, an appropriate interval of Pap smear screening cannot be concluded from the present
study. Nevertheless, the HIV-infected Thai women may require more than two normal semi-annual Pap smears
before shifting to routinely annual cytologic screening.
Background
Thailand is one of the world’s endemic areas for HIV
infection. In 2007, approximately 250,000 women were
living with HIV infection [1]. Women living with HIV-
AIDS clearly have an increased risk of cervical cancer. A
recent study in HIV-infected women in Thailand found
that cervical cancer was the most common AIDS-related
malignancy[2]. Sufficient Papanicolaou (Pap) smear
screening would render a high yield in early detection
because of its affordability, availability and accessibility.
Cervical squamous cell abnormalities in HIV-infected
women, compared with women who are not infected,
progress more rapidly to more significant cervical
intraepithelial neoplasia (CIN) or even invasive cervical
cancer[3].
Our previous study indicated that 13.3% of HIV-infected
pregnant women had cervical squamous cell abnormalities
[4], while the prevalence of abnormal Pap smears from
many studies seemed to be higher (20%-40%)[5-8]. How-
ever, there are different backgrounds. Many studies
reported that cytology was primarily subject to false
negative results[3,7,9-12]. Even with a negative for intrae-
pithelial lesion (NIL) with an initial Pap smear, 20% of
HIV-infected women will be later found with biopsy-con-
firmed cervical squamous cell intraepithelial lesions (SILs)
in 3 years[3]. This may either reflect an incident lesion or
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a study aimed at evaluating the sensitivity and specificity
of Pap smears showed that 38% of all CIN would have
been missed if routine colposcopy and biopsy had not
been performed[7].
HIV treatment guidelines issued by The US Public
Health Service and The Infectious Disease Society of
America have recommended that all HIV-infected
women should obtain two Pap smears 6 months apart
after an initial HIV diagnosis and, if the results of both
are normal, these women should then undergo annual
cytologic screening[13]. However, the guideline has not
been revised since 1995 and there has been no evi-
dence to support that this guideline is appropriate in
all settings, especially for HIV-infected women living
in resource-constrained conditions where long-term
studies are difficult to conduct. Moreover, currently no
national cervical screening guidelines are in use in
Thailand.
For these reasons, semi-annual Pap smear screenings
for all HIV-infected Thai women, (not only women with
CD+ 4 counts <200 cells/μL), development of health
education and improved efforts to increase the trust
between health care providers and women, have been
implemented in our clinic since 2004. The present study
aimed to determine an appropriate strategy for Pap
smear screening and risk factors related to subsequent
abnormal cervical cytology. Prevalence, cumulative
incidence and associated factors of cervical cell abnorm-
alities (atypical squamous cell of undetermined signifi-
cance; ASCUS or higher grades, i.e. atypical squamous
cells cannot exclude high grade squamous intraepithelial
lesion; ASC-H, low grade squamous intraepithelial
lesion; LSIL, High grade squamous intraepithelial lesion;
HSIL, squamous cell carcinoma) designated as ASCUS+
among this group of patients were assessed.
Methods
With the program implementation of semi-annual Pap
smear screening for all HIV-infected women at the
Female Sexually Transmitted Disease Clinic (STD
Clinic), Faculty of Medicine Siriraj Hospital, Mahidol
University from January 2004 to December 2009, the
STD-medical records of 901 HIV-infected women were
available for review to search for the results from first
Pap smears. In our clinical protocol, all HIV-infected
women were counselled to receive baseline Pap smear
screening, and were required to come back for the next
screening every 6 months. Sociodemographic data were
collected using a structured medical record form. Blood
sample for CD4+ count was obtained every 6 months.
The result was determined in a local laboratory con-
ducted by the Department of Microbiology in our
hospital.
After a clinical and pelvic examination, women with
signs of STDs were counselled and treated, and asked to
return to the clinic 2 weeks later for baseline Pap smear
screening. All Pap smear specimens were obtained by
gynaecologists from the endocervix, cervical transforma-
tion zone and discharge at posterior fornix of vagina
using a cotton tip stick and Ayre spatula, as described
in the VCE technique. Cytological analyses were under-
taken at the Division of Cytology of Department of
Obstetrics and Gynaecology, Faculty of Medicine Siriraj
Hospital. All Pap smear tests were processed and read
by our certified senior cytotechnologists based on the
2001 Bethesda system guideline[14]. According to our
policy, colposcopy must be offered in all cases of
ASCUS+, but due to the occurrence of lost to follow-
up, some of them were not able to have colposcopy. If
indicated by colposcopy or cytology results, lesions were
further evaluated by biopsy, endocervical curettage, or
loop electrical excision. Definite surgical treatment (hys-
terectomy) was provided as indicated[15].
Participants who initially had NIL and came for their
second Pap smear screening were included in the sub-
group analysis to assess the cumulative incidence and
factors associated with ASCUS+: namely age, parity,
abortion, contraceptive methods, antiretroviral treatment,
assumed duration HIV infection, CD4 count nadir and
baseline CD4 count. All women with subsequent
ASCUS/LSIL were not repeatedly enrolled among the
rest of the study population. The assumed duration HIV
infection was the duration that was estimated by the
patient after counseling and the CD4 count nadir was the
lowest CD4 count recorded. Data entry and analysis was
performed by SPSS version 13 (SPSS, Chicago, IL, USA).
Data were presented as frequency, percentage, mean ±
standard deviation (SD), or median with ranges as appro-
priate. The cumulative incidence of ASCUS+ was esti-
mated over the course of this study using standard life
table methods. The student’s t-test was used to compare
means and Pearson X
2-test or Fisher’se x a c tt e s tw a s
used to compare proportions between HIV-infected
women with ASCUS+ and NIL at first Pap smear, and
between HIV-infected women with subsequent ASCUS+
and NIL who had a NIL at first Pap smear. Statistically
significant differences were defined as p < 0.05. The
Mann Whitney U test was used for variables that were
not normally distributed. Multivariate correlation analysis
was used to adjust for potential confounding factors. The
study was conducted in accordant with the ethics princi-
ple of declaration of Helsinki, and the study protocol was
approved by the Siriraj Institutional Review Board.
Results
Of 901 HIV-infected women, 80 women were excluded
as 18 women did not received Pap smear screening, 12
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Page 2 of 7women did not have an intact cervix at baseline, 31
women had a previous diagnosis or treatment of cervical
intraepithelial neoplasia, and 19 women had no docu-
mentation of CD4+ count. As a result, 821 women were
included in the analysis. The study population had a
mean age of 30.1 years (range 14 - 65), a median base-
line CD4 count of 324 cells/μL (range 2 - 999) and a
median CD4 count nadir of 206 cells/μL (range 2 - 930).
Of the 821 women, 237 women (28.9%) had CD4
counts less than 200 cells/μL and 395 women (48.1%)
were receiving highly active antiretroviral therapy
(HAART). There were 443 women who initially came to
the clinic for antenatal care (ANC), 43 women for post-
partum Pap smear screening, 37 women with STD
related problems or positive pre-operative gynaecologic
anti-HIV screening, and 298 women referred from the
HIV clinic, Department of Preventive Medicine, for Pap
smear screenings. The Pap smear screening data were
from the women’s first 12 semi-annual visits (over a per-
iod of 5.5 years) and consisted of 2,852 Pap smear tests.
Prevalence of ASCUS+
The prevalence of cervical squamous cell abnormalities
from 821 initial Pap smear screenings was 15.4%, consist-
ing of ASCUS 2.8%, atypical squamous cells cannot
exclude high grade squamous intraepithelial lesion
(ASC-H) 0.6%, LSIL 8.5%, and HSIL 3.5% (Table 1). The
most common coincident genital infection was fungal
infection at 19.4% of the women. Compared with women
with NIL, those with ASCUS+ had significantly higher
proportions of receiving HAART and the baseline CD4
count <200 cells/μL (58.3% vs. 46.3%, 37.8% vs. 28.2%,
respectively). A higher proportion of baseline CD4 count
<350 cells/μL was also found in women with ASCUS+
(66.9% vs. 52.4%). In addition they had a significantly
longer mean of assumed duration of HIV infection but a
lower mean of CD4 count nadir (7.1 ± 4.1 years vs. 5.9 ±
3.4 years and 188.9 ± 142.7 cells/μL vs. 239.9 ± 182.8
cells/μL, respectively) as shown in Table 2.
Cumulative incidence of ASCUS+
Of the 444 women who had NIL at initial Pap smear
screening and came for the second test, the cumulative
incidence of ASCUS+ was 15%. The cumulative inci-
dence was gradually increased in the first 7 visits to 37%
and tended to plateau in the last 4 visits (Figure 1).
There was a median follow-up time of 12 months when
the first ASCUS+ was detected. The mean and median
number of Pap smears per patient was 2.7 and 2.0,
respectively. None of the patients got pregnant during
the follow-up visits in this study. There was no statisti-
cal difference between development of ASCUS+ from
NIL in terms of age, number of abortions, contraceptive
methods, receiving HAART, assumed duration of HIV
infection, or CD4 count nadir level. However, the pro-
portion of multipara women and women with CD4
count < 200 cells/μL showed statistically significant dif-
ferences between the two groups (84.2% vs. 72.8%,
p 0.022; 37.9% vs.20.9%,p= 0.016, respectively). In addi-
tion the proportion of women with CD4 count < 350
cells/μL was still significantly higher (62.1% vs.48.4%,
Table 1 Frequency of cervical cytological findings at the
first visit
Cervical cytological findings Frequency
(cases)
Percent
Negative for intraepithelial lesion
Without organism and inflammation 412 50.2
Candida and budding yeasts 159 19.4
Trichomonas vaginalis 13 1.6
Bacterial vaginosis 2 0.2
Herpes simplex virus 12 1.5
Reactive cellular changes associated with
inflammation
96 11.7
Squamous cell abnormalities
ASCUS 23 2.8
ASC-H 5 0.6
LSIL 70 8.5
HSIL 29 3.5
Total 821 100
ASCUS, atypical squamous cell of undetermined significance; ASC-H, atypical
squamous cell cannot exclude HSIL; LSIL, low grade squamous intraepithelial
lesion;
HSIL, high grade squamous intraepithelial lesion.
Table 2 Comparison of the baseline characteristics of
women with ASCUS+ and NIL at first Pap smear
ASCUS+
(N = 127)
NIL
(N = 694)
P
Age (yrs) 30.9 ± 8.4 29.8 ± 7.1 0.080
Gravidarum ≥ 1 102 (80.3) 592 (85.3) 0.153
Parity ≥ 1 93 (73.2) 526 (75.8) 0.537
Abortion ≥ 1 37 (29.1) 226 (32.6) 0.446
Contraception
Tubal sterilization 55 (34.3) 372 (53.6) 0.076
Condom 50 (39.4) 237 (34.1)
Others 22 (17.3) 85 (12.2)
Time since assumed infection
(yrs)
7.1 ± 4.1 5.9 ± 3.4 0.001
#
Receiving HAART 74 (58.3) 321 (46.3) 0.013
Baseline CD4 count
< 350 cells/μL
85 (66.9) 364 (52.4) 0.003
CD4 count nadir (cells/μL) 188.9 ±
142.7
239.9 ±
182.8
0.000
Data are mean ± standard deviation or n (%).
# Mann-Whitney U test.
ASCUS+, atypical squamous cell of undetermined significance or higher
grades;
NIL, negative for intraepithelial lesion; HAART, highly active antiretroviral
therapy.
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adjusted for multiparity women and CD4 count < 350
demonstrated that the CD4 count <350 cells/μL was the
only significant risk factor for developing subsequent
ASCUS+ (p = 0.043).
Colposcopic and histologic diagnosis of ASCUS+
Of the 95 women with subsequent ASCUS+, 16 (16.8%)
had ASCUS, 1 (1.1%) had ASC-H, 60 (63.2%) had LSIL and
18 (18.9%) had HSIL (data not shown). Seventy six women
were able to undergo colposcopic investigation and 19 of
them (25.0%) were subsequently colposcopically-diagnosed
CIN II-III (Table 4). Nineteen of twenty-four women who
were colposcopically diagnosed CINII-III and/or cytologi-
cally diagnosed HSIL were able to undergo loop electrical
excision procedure of cervix (LEEP) or cold knife coniza-
tion at this hospital. There were histological assessments
which confirmed CIN II-III in 12/19 (63%) and invasive
squamous carcinoma in 1/19 (5.3%).
Discussion
This is the first long-term retrospective cohort study of
cervical squamous cell abnormalities in HIV-infected
Figure 1 Cumulative incidence of ASCUS+.
Table 3 Comparison of the baseline characteristics of
women with subsequent ASCUS+ and NIL who had a NIL
at first Pap smear
ASCUS+
(N = 95)
NIL
(N = 349)
P
Age (yrs) 30.0 ± 8.7 30.1 ± 7.0 0.901
Gravidarum ≥ 1 85 (89.5) 299 (85.7) 0.337
Parity ≥ 1 80 (84.2) 254 (72.8) 0.022
Abortion ≥ 1 23 (24.2) 115 (33.0) 0.103
Contraception
Tubal sterilization 60 (63.2) 198 (56.7) 0.187
Condom only 28 (29.5) 101 (28.9)
Others 7 (7.4) 50 (14.3)
Time since assumed infection
(yrs)
6.1 ± 2.7 5.9 ± 3.0 0.661
#
Receiving HAART 52 (54.7) 160 (45.8) 0.124
Baseline CD4 count
< 350 cells/μL
59 (62.1) 169 (48.4) 0.018
CD4 count nadir (cells/μL) 206.3 ±
149.4
244.9 ±
189.1
0.067
#
Data are mean ± standard deviation or n (%).
# Mann-Whitney U test.
HAART, highly active antiretroviral therapy; ASCUS+, atypical squamous cell of
undetermined significance or higher grades; NIL, negative for intraepithelial
lesion.
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infections have a higher prevalence, incidence, persis-
tence, and progression of squamous intraepithelial
lesions as compared with those without the infection.
The prevalence of cervical squamous cell abnormalities
and SILs in the present study was similar to that in our
previous study[4]. Compared with several previous stu-
dies[5-8], the result of Pap smear screenings from the
present study showed a slightly lower prevalence (15.4%
vs.20%-40%). In addition to the different backgrounds,
this may be due to the fact that the majority of partici-
pants in this study were either ante-partum, or immedi-
ate postpartum.
Interestingly, the cumulative incidence of ASCUS+ in
the present study gradually increased to 37% in the first
3.5 years of follow-up appointments (first 7 times) and
tended to plateau in the last 2 years. In addition, one
woman with cytological diagnosis of HSIL and with a
histologic diagnosis of CINIII was diagnosed from the
Pap smear at her seventh follow-up appointment. Com-
parable with this study, a previous study found that
among HIV- infected women whose initial Pap smear
was negative for intraepithelial lesion (NIL), about 20%-
35% of them would develop cytologic abnormalities over
3.0-5.5 years[3]. This supports the fact that there is a
high rate of false negative Pap smear results among
HIV-infected patients, as mentioned in a previous study
[16]. The findings prompted us to reconsider the appro-
priate interval of Pap smear screenings for HIV-infected
women as recommended by The US Public Health Ser-
vice and The Infectious Disease Society of America in
our setting. Our population might require more than
two normal semi-annual Pap smear before shifting to
annual cytologic screening. As the present study had
high drop-out rate in the first 2 years, we believe that
the real incidence of ASCUS+ might be higher. Previous
studies have base analysis on less frequent Pap smears
than ours; some of them did not pay sufficient attention
to the lag period which is supposed to play an important
part in cervical carcinogenesis.
Many studies demonstrated that women with a CD4
count < 200 cells/μL were at particular risk of cervical
cell abnormalities[4,16-19]. This means that immunolo-
gical status also plays a crucial part in cervical carcino-
genesis. We found that the women with ASCUS+ had
significantly higher proportions of receiving HAART
than those with NIL. This is the most likely reflection
that these women had an underlying poor immune sta-
tus by their own merit without any correlation of
H A A R T .T h eC D 4c o u n tc u t - o f fp o i n tt h a tw eu s e dt o
predict cumulative incidence of ASCUS+ was 350 cells/
μL, which is compatible with a study from Brazil[19].
Recently, the Thai Ministry of Public Health initiates
HAART for all HIV-infected patients who have CD4
counts at this level or lower. The CD4 counts < 200
cells/μL seem to be far too low to detect new ASCUS+
cases and may be too low for basing a decision to initi-
ate HAART regimen. However, we did not look at the
change of CD4 count and its impact on cumulative inci-
dence of ASCUS+.
A well-designed study demonstrated that the inci-
dence of SILs increased with time, especially the ones
with lower CD4 count and oncogenic HPV infection
[17]. In addition, a study from Italy with 132 HIV-
infected women who had invasive cervical cancer (ICC)
showed that the interval between the first HIV-positive
test and invasive cancer diagnosis was longer than 10
years in almost half of the women[20]. We also found
that the assumed duration of HIV infection and the
CD4 count nadir level were associated with a high pre-
valence of ASCUS+ from the initial Pap smear. How-
ever, they were not associated with the cumulative
incidence of ASCUS+.
In the present study only 0.1% (1/821) of HIV-infected
women had invasive squamous cell carcinoma. This
woman had a baseline CD4 count of 148 cells/μLa n d
had a 14-year duration assumed HIV infection. She had
a cytologic HSIL at the third Pap smear and colposcopic
diagnosis of HSIL. With a lower incidence of invasive
squamous cell carcinoma, our study may not represent
the whole picture of HIV-infected women in Thailand -
since the incidence in this study was lower than the fig-
ure reported from a previous study conducted in Thai-
land[21]. A high number of women were already on
HAART at commencement of the study. HAART might
have beneficially protective on preventing cervical carci-
nogenesis[22,23]. More important reasons were the early
detection by a regular semi-annual check-up, the devel-
opment of health education, and the growth of trust
between health care providers and patients. Smoking
was not included in the baseline characteristics because
almost all Thai women were not current or ex-smokers.
Several studies are currently investigating the benefits
o fa d d i n gH P VD N At e s t st oi m p r o v es c r e e n i n gf o r
Table 4 Colposcopic results in women with abnormal Pap
smears
Colposcopic results n(%)
Abmornal Pap smears N Normal HPV/CIN I CIN II-III
ASCUS 14 4 (28.6) 9 (64.3) 1 (7.1)
LSIL 46 3 (6.5) 36 (78.3) 7 (15.2)
HSIL 16 0 5 (31.3) 11 (68.7)
Total 76 7(9.2) 50 (65.8) 19 (25.0)
ASCUS, atypical squamous cell of undetermined significance
LSIL, low grade squamous intraepithelial lesion
HSIL, high grade squamous intraepithelial lesion
HPV, human papilloma virus
CIN I, cervical intraepithelial neoplasia I
CINII-III, cervical intraepithelial neoplasia II-III
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HPV types is a more sensitive predictor of high grade
squamous intra-epithelial lesions. Overall, the HPV test
had a higher sensitivity among HIV-infected women as
compared with HIV-uninfected women. One study in
Thailand reported that the prevalence of high risk HPV
infection in Thai HIV-seropositive women was 38.6%
[21], which was lower than that found in American
(83.2%) and Brazilian women (44.5%)[24,25]. However,
HPV DNA testing is not a routine screening test in this
clinic due to its high cost. In addition, the specificity for
cervical lesions of the test was low in HIV-infected
women, resulting largely from a very high prevalence of
HPV infection in women without cervical lesions. Thus,
a HPV test may not provide benefits for cervical surveil-
lance in the setting of HIV, because of its low specificity
and poor predictive value[26,27].
In 1999, Holcomp, et al. demonstrated the significance
of ASCUS in HIV-infected women by comparing cytolo-
gical and histological results[28]. They found that 32%
of ASCUS had histological cervical intraepithelial neo-
plasia (CIN). As a result, they suggested that early col-
poscopy should be considered in HIV infected women
with ASCUS. There were a total of 16 women with
ASCUS in our study, 14 were able to undergo colpo-
scopy and 10 had colposcopic diagnosis of SILs (9
women with HPV/CIN I and 1 woman with CIN II-III)
(Table 4). Although our studyd e m o n s t r a t e dt h a tt h e r e
was a high incidence of colposcopic diagnosis of SILs in
women with ASCUS, only one woman in this group had
colposcopic diagnosis of CIN II-III which had to be con-
firmed by tissue diagnosis. Since most of them had col-
poscopic diagnosis of HPV/CIN I and had a low socio-
economic background, it was unlikely that biopsies with
pathological reports in these cases could be met.
There were a number of limitations in the present
study that warranted mentioning. (1) The primary out-
come was mainly the surrogate outcome of cervical can-
cer. Even though the incidence of abnormal lesions was
high, these were mainly low grade lesions which could
be regression, especially in younger women[29]. (2)
False negative Pap smear was not included in the scope
of the present study and this might have impact the
findings as a previous study found a high false negative
Pap smear rate in HIV-infected women with CD4 count
< 500 cells/μL[16]. (3) The lack of viral load, colposcopy
with tissue biopsy could not be performed in all cases;
instead, a ‘see and treat’ technique was applied in order
to decrease costs. (4) Due to the government universal
coverage program and limited seats at Siriraj Hospital,
many participants, especially a number in our study who
were either ante-partum, or immediate post partum,
were required to follow-up at their registered hospitals
causing 250 women to be lost to follow up by the 6
m o n t hv i s i t( 3 6 % )a n daf u r t h e r1 3 3( 2 0 % )l o s ta t1 2
months. This is a loss of over 50% of study participants
in the first year of follow-up. In addition, an effort to try
to establish some relationship between health care pro-
viders and HIV- infected women was very difficult
because of stigmatization of HIV. As a consequence, the
rate of follow-up was quite low leading to the potential
biases, such as survivorship bias/retention in care. In
addition, other AIDS-indicated conditions and estab-
lished risk factors of cervical cancer were not accounted
for and there was one patient who died from an oppor-
tunistic infection during the follow-up period.
Conclusions
There are high prevalence and cumulative incidence of
ASCUS+ in HIV-infected Thai women. With a high
lost-to-follow-up rate, an appropriate interval of Pap
smear screening cannot be concluded from the present
study. Nevertheless, the HIV-infected Thai women may
require more than two normal semi-annual Pap smears
before shifting to routinely annual cytologic screening.
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